Camargo-Ayala, LorenaBedoya, MauricioDasí, AlbertPrüser, MertenSchütte, SvenPrent-Peñaloza, LuisAdasme-Carreño, FranciscoKiper, Aytug K.Rinné, SusanneCamargo-Ayala, Paola AndreaPeña-Martínez, Paula A.Bueno-Orovio, Alfonso2025-05-192025-05-192025-04Journal of Biological Chemistry Volume 301, Issue 4 April 2025 Article number 1083870021-9258https://repositorio.unab.cl/handle/ria/64735Indexación (Scopus)Atrial fibrillation (AF) involves electrical remodeling of the atria, with ion channels such as NaV1.5, KV1.5, and TASK-1 playing crucial roles. This study investigates acetamide-based compounds designed as multi-target inhibitors of these ion channels to address AF. Compound 6f emerged as the most potent in the series, demonstrating a strong inhibition of TASK-1 (IC50 ∼ 0.3 μM), a moderate inhibition of NaV1.5 (IC50 ∼ 21.2 μM) and a subtle inhibition of KV1.5 (IC50 ∼ 81.5 μM), alongside unexpected activation of TASK-4 (∼ 40% at 100 μM). Functional assays on human atrial cardiomyocytes from sinus rhythm (SR) and patients with AF revealed that 6f reduced action potential amplitude in SR (indicating NaV1.5 block), while in AF it increased action potential duration (APD), reflecting high affinity for TASK-1. Additionally, 6f caused hyperpolarization of the resting membrane potential in AF cardiomyocytes, consistent with the observed TASK-4 activation. Mathematical modeling further validated its efficacy in reducing AF burden. Pharmacokinetic analyses suggest favorable absorption and low toxicity. These findings identify 6f as a promising multi-target therapeutic candidate for AF management.enatrial fibrillationion channelsK2P channelsKV1.5multi-target inhibitorsNaV1.5PolypharmacologyArtículo10.1016/j.jbc.2025.108387